This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo Gets FDA Clearance for Rad-67 Monitoring Device
by Zacks Equity Research
The clearance will enable Masimo (MASI) to provide portable spot-checking monitoring measurements of oxygen saturation and non-invasive hemoglobin.
Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip
by Zacks Equity Research
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.
AMN Healthcare Down on Soft Locum Tenens Business, Dull View
by Zacks Equity Research
Dependence on third parties is detrimental for AMN Healthcare (AMN).
Senseonics Unveils Eversense Bridge Program in the U.S.
by Zacks Equity Research
The Eversense Bridge program aligns with Senseonics' (SENS) strategy of offering innovative yet affordable and hassle-free medical care to diabetic patients.
Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue
by Zacks Equity Research
Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.
Varian (VAR) Scales New 52-Week High on Solid Prospects
by Zacks Equity Research
The key growth driving factor for Varian (VAR) in the past year has been increasing net sales from major business segments.
Moving Average Crossover Alert: Penumbra
by Zacks Equity Research
Penumbra, Inc. (PEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
Recently, Cerner (CERN) expanded its reach in the Alabama rural health care market through a new collaboration.
Stryker (SYK) Scales a New 52-Week High on Solid Prospects
by Zacks Equity Research
The key growth-driving factor for Stryker (SYK) in the past year has been increasing net sales from each of its three major business segments.
Inogen's Prospects in Europe Solid Amid Trade-Related Tension
by Zacks Equity Research
Inogen's (INGN) business-to-business unit sees strength in Europe.
Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4
by Zacks Equity Research
Veeva Systems' (VEEV) broad spectrum of products include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData.
Integra's Duragen Secures Japanese Nod to Drive Global Growth
by Zacks Equity Research
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.
Haemonetics' Plasma Unit Grows, Global Expansion on Track
by Zacks Equity Research
Haemonetics' (HAE) Plasma arm steadily witnesses solid growth in the fiscal third quarter on 16% revenue rise at constant currency.
Hill-Rom's Buyout of Voalte to Bolster Digital Connectivity
by Zacks Equity Research
Hill-Rom (HRC) anticipates Voalte acquisition to be modestly dilutive to its adjusted EPS in fiscal 2019.
Invitae (NVTA) Scales a New 52-Week High on Solid Prospects
by Zacks Equity Research
One of the key growth drivers for Invitae (NVTA) is an increase in billable tests over the past year.
ResMed's New Brightree Suite to Boost Home Infusion Business
by Zacks Equity Research
ResMed's (RMD) Brightree suite upgrade will help uplift business operations by easily meeting compliance needs and offering the best quality patient care.
Cooper Companies (COO) Hits 52-Week High on Solid Prospects
by Zacks Equity Research
Cooper Companies' (COO) revenues across CooperVision and CooperSurgery see growth.
Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Penumbra (PEN) sees strength across all segments in Q4.
Integra Rides on Channel Expansion Strategy, New Alliances
by Zacks Equity Research
Integra's (IART) success with its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
ResMed Inks Deal With PharMerica on Medication Management
by Zacks Equity Research
The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.
DexCom (DXCM) Gets Health Canada Approval for G6 CGM System
by Zacks Equity Research
DexCom's (DXCM) G6 CGM system intends to serve diabetes patients of all age groups in Canada.
Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) continues to gain on solid international business.
Quest Diagnostics Grows on Innovation Amid Reimbursement Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.